MYCi975

製品コードS8906 バッチS890601

印刷

化学情報

Synonyms

NUCC-0200975

Storage
(From the date of receipt)

3 years -20°C powder

化学式

C₂₅H₁₆Cl₂F₆N₂O₂

分子量

561.30

CAS No.

2289691-01-4

Solubility (25°C)*

体外

DMSO

100 mg/mL (178.15 mM)

Ethanol

60 mg/mL (106.89 mM)

Water

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	1.670mg/ml (2.98mM)	Taking the 1 mL working solution as an example, add 50 μL of 33.3 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to make it clear. Volume up to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	MYCi975（NUCC-0200975）は、MYC/MAX相互作用を阻害し、MYC T58リン酸化とMYC分解を促進し、MYC駆動遺伝子発現を損なう、強力で選択的かつ経口活性型のMYC阻害剤です。MYCi975は強力な抗腫瘍活性を示します。
in vitro	MYCi975 localizes to the same region of the MYC protei. Treatment of cells with this compound enhances MYC degradation and phosphorylation on T58. It also directly increases GSK3b-mediated MYC pT58 in the in vitro kinase assay.
in vivo	MYCi975 suppresses in vivo tumor growth in mice, increases tumor immune cell infiltration, upregulates PD-L1 on tumors, and sensitizes tumors to anti-PD1 immunotherapy with good tolerability.

プロトコル(参考用のみ)

細胞アッセイ	細胞株	MycCaP, PC3, LNCaP, PC12, MV411, SK-N-BE (2), 293T, P493-6 B cells, LLC1 cells, TGR-1, HO15.19 Rat-1 cells
	濃度	3-25 μM, 8 μM, 6 μM
	反応時間	24 h
	実験の流れ	PC3 cells are treated with 6 μM 361 or 8 μM MYCi975 and P493-6 cells are treated with 0.1 mg/ml Tetracycline or 6 μM this compound for 24 hr in triplicates. Then cells are washed with PBS and RNA is extracted using RNAeasy Plus mini kit.
動物実験	動物モデル	6-8 weeks old FVB mice, prostate PDX model (TM00298), NSG mice, C57BL/6, CB17/Icr-Prkdcscid/IcrIcoCrl mice, CD-1
	投薬量	50 mg/kg, 100 mg/kg
	投与方法	IP

参考

https://pubmed.ncbi.nlm.nih.gov/31679823/
https://pubmed.ncbi.nlm.nih.gov/35108425/
https://pubmed.ncbi.nlm.nih.gov/36211811/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Reprogramming neuroblastoma by diet-enhanced polyamine depletion [ Nature, 2025, 646(8085):707-715]	PubMed: 40993392
MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer [ Cell Rep, 2025, 44(6):115722]	PubMed: 40392656
Defining the functional role and potential as an immunotherapeutic target of ALCAM in neuroblastoma [ Mol Cancer Ther, 2025, 10.1158/1535-7163.MCT-25-0136]	PubMed: 41202161
CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer [ Transl Oncol, 2025, 57:102414]	PubMed: 40381484
Cell-based high-throughput screening using a target-NanoLuc fusion construct to identify molecular glue degraders of c-Myc oncoprotein [ RSC Chem Biol, 2025, 10.1039/d5cb00093a]	PubMed: 40978459
Substrate Stiffness Modulates Fibroblast Extracellular Vesicle Secretion via Mechanotransduction Pathways [ bioRxiv, 2025, 2025.07.29.667440]	PubMed: 40766685
Metabolic imaging distinguishes ovarian cancer subtypes and detects their early and variable responses to treatment [ Oncogene, 2024, 10.1038/s41388-024-03231-w]	PubMed: 39639170
The oncogenic axis YAP/MYC/EZH2 impairs PTEN tumor suppression activity enhancing lung tumorigenicity [ Cell Death Discov, 2024, 10(1):452]	PubMed: 39455556
A program of successive gene expression in mouse one-cell embryos [ Cell Rep, 2023, 42(2):112023]	PubMed: 36729835
Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics [ Cancer Res, 2022, 82(7):1174-1192]	PubMed: 35180770

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。